

# Wen Lu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8278571/publications.pdf>

Version: 2024-02-01

12  
papers

84  
citations

1684188  
5  
h-index

1474206  
9  
g-index

12  
all docs

12  
docs citations

12  
times ranked

124  
citing authors

#	ARTICLE	IF	CITATIONS
1	Unusual non-platelet predominant clumping in a hematopoietic progenitor cell apheresis collection bag. <i>Transfusion</i> , 2022, 62, 931-932.	1.6	0
2	Unmasking delayed hemolytic transfusion reactions in patients with sickle cell disease: Challenges and opportunities for improvement. <i>Transfusion</i> , 2022, 62, 1662-1670.	1.6	2
3	Hospital red blood cell and platelet supply and utilization from March to December of the first year of the COVID-19 pandemic: The BEST collaborative study. <i>Transfusion</i> , 2022, 62, 1559-1570.	1.6	6
4	Implementation of a Standardized Prenatal Testing Protocol in an Integrated, Multihospital Health System. <i>American Journal of Clinical Pathology</i> , 2021, 155, 133-140.	0.7	4
5	The use of therapeutic plasma exchange as adjunctive therapy in the treatment of coronavirus disease 2019: A critical appraisal of the current evidence. <i>Journal of Clinical Apheresis</i> , 2021, 36, 483-491.	1.3	16
6	Perfusion quality-of-life assessment for patients with myelodysplastic syndromes. <i>Transfusion</i> , 2021, 61, 2830-2836.	1.6	10
7	A Concise Synopsis of Current Literature and Guidelines on the Practice of Plasma Transfusion. <i>Clinics in Laboratory Medicine</i> , 2021, 41, 635-645.	1.4	0
8	Fellowship training programs in blood banking/transfusion medicine in the United States, 2016-2020. <i>Transfusion</i> , 2021, 61, 2801-2802.	1.6	3
9	A national survey of hospital-based transfusion services on their approaches to platelet bacterial risk mitigation in response to the FDA final guidance for industry. <i>Transfusion</i> , 2020, 60, 1681-1687.	1.6	8
10	How do you decide which platelet bacterial risk mitigation strategy to select for your hospital-based transfusion service?. <i>Transfusion</i> , 2020, 60, 675-681.	1.6	4
11	Platelets treated with pathogen reduction technology: current status and future direction. <i>F1000Research</i> , 2020, 9, 40.	1.6	17
12	Effect of bone marrow CD34+ cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 775-781.	2.4	14